搜尋
MoonLake Immunotherapeutics
MLTX添加自選
17.550USD
-0.840-4.57%
收盤 05/15, 16:00（美東）報價延遲15分鐘
1.29B總市值
虧損本益比TTM
關於 MoonLake Immunotherapeutics 公司
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeutics簡介
公司代碼MLTX
公司名稱MoonLake Immunotherapeutics
上市日期Oct 20, 2020
CEOSantos Da Silva (Jorge)
員工數量100
證券類型Ordinary Share
年結日Oct 20
公司地址Dorfstrasse 29
城市ZUG
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Switzerland
郵編6300
電話41415108022
網址https://moonlaketx.com/
公司代碼MLTX
上市日期Oct 20, 2020
CEOSantos Da Silva (Jorge)
MoonLake Immunotherapeutics公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.96M
-5.66%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.19M
-7.61%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.96M
-5.66%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.19M
-7.61%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 5月14日 週四
更新時間: 5月14日 週四
持股股東
股東類型
持股股東
持股股東
佔比
BVF Partners L.P.
21.74%
Deep Track Capital LP
6.26%
Cormorant Asset Management, LP
5.92%
Reich (Kristian)
4.09%
Santos da Silva (Jorge)
4.01%
其他
57.98%
持股股東
持股股東
佔比
BVF Partners L.P.
21.74%
Deep Track Capital LP
6.26%
Cormorant Asset Management, LP
5.92%
Reich (Kristian)
4.09%
Santos da Silva (Jorge)
4.01%
其他
57.98%
股東類型
持股股東
佔比
Hedge Fund
49.10%
Individual Investor
9.97%
Investment Advisor
8.58%
Research Firm
6.25%
Investment Advisor/Hedge Fund
6.20%
Venture Capital
3.81%
Sovereign Wealth Fund
0.32%
Bank and Trust
0.09%
Pension Fund
0.06%
其他
15.63%
機構持股
更新時間: 4月1日 週三
更新時間: 4月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
358
54.44M
74.73%
-3.15M
2025Q4
350
44.19M
62.38%
-21.09M
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BVF Partners L.P.
19.75M
27.88%
--
--
Nov 06, 2025
Deep Track Capital LP
4.61M
6.51%
+4.61M
--
Nov 05, 2025
Cormorant Asset Management, LP
1.99M
2.81%
-6.50M
-76.52%
Sep 30, 2025
Reich (Kristian)
2.96M
4.18%
-167.52K
-5.35%
Dec 19, 2025
Santos da Silva (Jorge)
3.07M
4.34%
-3.68K
-0.12%
Dec 19, 2025
D. E. Shaw & Co., L.P.
2.48M
3.46%
+2.48M
--
Dec 31, 2025
Janus Henderson Investors
2.10M
2.92%
+2.08M
+18782.77%
Dec 31, 2025
Logos Global Management LP
1.75M
2.44%
+1.75M
--
Dec 31, 2025
Balyasny Asset Management LP
1.70M
2.4%
+1.28M
+301.55%
Sep 30, 2025
Bodenstedt (Matthias)
922.01K
1.3%
+294.47K
+46.93%
Dec 19, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.22%
Virtus LifeSci Biotech Clinical Trials ETF
0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
Strive Small-Cap ETF
0.02%
Nuveen ESG Small-Cap ETF
0.02%
iShares Morningstar Small-Cap ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
查看更多
ALPS Medical Breakthroughs ETF
佔比0.27%
Global X Guru Index ETF
佔比0.22%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.02%
Strive Small-Cap ETF
佔比0.02%
Nuveen ESG Small-Cap ETF
佔比0.02%
iShares Morningstar Small-Cap ETF
佔比0.01%
John Hancock Multifactor Small Cap ETF
佔比0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
佔比0.01%
Fidelity Nasdaq Composite Index ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
